Share on StockTwits

Shares of Perrigo Company PLC (NASDAQ:PRGO) fell 8.4% on Wednesday following a weaker than expected earnings announcement, American Banking reports. The stock traded as low as $129.30 and last traded at $130.99, with a volume of 2,353,960 shares changing hands. The stock had previously closed at $142.99.

The company reported $1.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.51 by $0.20. The company had revenue of $1,000.00 million for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the company posted $1.42 earnings per share. The company’s revenue for the quarter was up 9.1% on a year-over-year basis.

The company also recently declared a quarterly dividend, which is scheduled for Tuesday, June 17th. Stockholders of record on Friday, May 30th will be given a dividend of $0.105 per share. This represents a $0.42 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date of this dividend is Wednesday, May 28th.

A number of research firms have recently commented on PRGO. Analysts at Jefferies Group reiterated a “buy” rating on shares of Perrigo Company PLC in a research note on Wednesday. They now have a $180.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $167.55.

The stock has a 50-day moving average of $150.2 and a 200-day moving average of $152.. The company has a market cap of $17.461 billion and a price-to-earnings ratio of 53.47.

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (NASDAQ:PRGO) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.